Initial Evaluation and Treatment for Newly Diagnosed HIV
Start antiretroviral therapy (ART) as soon as possible after HIV diagnosis—ideally within 7 days, including same-day initiation if the patient is ready and there is no suspicion of concomitant opportunistic infection. 1
Recommended Initial ART Regimens
The preferred first-line regimens are integrase strand transfer inhibitor (InSTI)-based combinations, specifically bictegravir or dolutegravir with two nucleoside reverse transcriptase inhibitors (NRTIs). 1 These regimens achieve the highest viral suppression rates with excellent tolerability, minimal toxicity, few drug interactions, high resistance barriers, and low pill burden.
Specific Recommended Regimens:
- Bictegravir/tenofovir alafenamide/emtricitabine (single-tablet, once daily)
- Dolutegravir/tenofovir alafenamide/emtricitabine
- Dolutegravir/abacavir/lamivudine (avoid if HLA-B*5701 positive)
- Dolutegravir/lamivudine (two-drug regimen option)
All carry an AIa evidence rating. 1, 2
Initial Laboratory Evaluation
Before or at treatment initiation, obtain:
- CD4+ T-cell count - determines disease stage and need for opportunistic infection prophylaxis
- Plasma HIV-1 RNA (viral load) - baseline measurement for monitoring response
- HIV genotypic resistance testing - identifies transmitted drug resistance
- Complete blood count, comprehensive metabolic panel - baseline organ function
- Hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody - screen for coinfections requiring specific management
- Sexually transmitted infection screening (syphilis, gonorrhea, chlamydia)
- Pregnancy test in persons of childbearing potential
- HLA-B*5701 testing if considering abacavir (contraindicated if positive)
- Tuberculosis screening - interferon-gamma release assay or tuberculin skin test
Special Considerations for Treatment Timing
Opportunistic Infections Present:
For most opportunistic infections: Start ART within 2 weeks of initiating treatment for the opportunistic infection 1
For tuberculosis:
- CD4 <50 cells/μL: Start ART within 2 weeks of TB treatment initiation
- CD4 ≥50 cells/μL: Start ART within 2-8 weeks of TB treatment
- TB meningitis: Delay ART 2-4 weeks after TB treatment starts, once meningitis is controlled 1
For cryptococcal meningitis: Start ART 2-4 weeks after antifungal therapy initiation, with timing based on clinical improvement, intracranial pressure control, and CSF culture clearance 1
Acute HIV Infection:
Immediate ART initiation is recommended - this represents a critical window for limiting viral reservoir establishment and preserving immune function 1
Pregnancy:
Immediate ART initiation is recommended regardless of CD4 count or viral load 1
Why InSTIs Are Preferred
The 2024 IAS-USA guidelines specifically prioritize bictegravir and dolutegravir over other InSTIs (raltegravir, elvitegravir) because:
- Higher barrier to resistance - viral suppression maintained even with suboptimal adherence
- Fewer drug interactions - particularly compared to elvitegravir/cobicistat
- Once-daily dosing - bictegravir and dolutegravir (raltegravir requires twice-daily dosing)
- Coformulated single-tablet options available
NRTI Backbone Selection
Tenofovir alafenamide (TAF) is generally preferred over tenofovir disoproxil fumarate (TDF) due to:
- Less renal toxicity (reduced proximal tubular dysfunction risk)
- Less bone mineral density loss
- Similar virological efficacy
However, TDF may be preferred in patients with:
- Dyslipidemia concerns (TDF lowers lipids more than TAF)
- Weight gain concerns (TAF associated with greater weight gain)
Common Pitfalls to Avoid
Do not delay ART for resistance testing results - start treatment immediately with a recommended regimen; adjust only if resistance is detected 1
Do not use dolutegravir/lamivudine two-drug regimen if:
- HIV RNA >500,000 copies/mL
- Hepatitis B coinfection present
- Resistance testing not yet available
- Planning rapid/same-day start
For tuberculosis coinfection, avoid bictegravir - significant drug interaction with rifampin. Use dolutegravir 50 mg twice daily, efavirenz, or raltegravir instead 2
Monitoring After Initiation
- Viral load at 4 weeks, then every 3 months until undetectable, then every 3-6 months
- CD4 count every 3-6 months initially, can extend to annually once >300 cells/μL and virally suppressed
- Treatment goal: HIV RNA <50 copies/mL (not just <200 copies/mL) to minimize resistance risk 2, 3
Addressing Structural Barriers
Remove barriers to same-day ART initiation including insurance authorization delays, pharmacy access issues, and transportation challenges. Evidence-informed strategies to support adherence and continuous access are critical for long-term success 1